Risankizumab

Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd 50 = 2 pM) . Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis[1][2][3].

Product Specifications

CAS Number

[1612838-76-2]

Product Name Alternative

Risankizumab rzaa; BI 655066; ABBV-066

UNSPSC

12352203

Target

Interleukin Related

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/risankizumab.html

Purity

99.37

Solubility

10 mM in DMSO

Smiles

[Risankizumab]

Molecular Weight

(145.92 kDa)

References & Citations

[1]McKeage K, Duggan S. Risankizumab: First Global Approval. Drugs. 2019 Jun;79 (8) :893-900.|[2]Andrea Chiricozzi, et al. Risankizumab for the treatment of moderate to severe psoriasis. Expert Opinion on Biological Therapy. Volume 19, 2019 - Issue 1|[3]Singh S, et al. Selective targeting of the IL23 pathway: Generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs. 2015;7 (4) :778-91.